Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...

The Lessie B. Price Center advertised their fitness programs for seniors and educational programs for youth at their open ...

The Columbia County Spring Fair is back in town, but this time with some policy changes amid disruptions last week.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Medically reviewed by Kelly Wood, MD Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.